Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Amy Jhatakia"'
Autor:
Natalie A. Bezman, Amy Jhatakia, Alper Y. Kearney, Ty Brender, Mark Maurer, Karla Henning, Misty R. Jenkins, Amy J. Rogers, Paul J. Neeson, Alan J. Korman, Michael D. Robbins, Robert F. Graziano
Publikováno v:
Blood Advances, Vol 1, Iss 12, Pp 753-765 (2017)
Abstract: Elotuzumab, a humanized monoclonal antibody that binds human signaling lymphocytic activation molecule F7 (hSLAMF7) on myeloma cells, was developed to treat patients with multiple myeloma (MM). Elotuzumab has a dual mechanism of action that
Externí odkaz:
https://doaj.org/article/b48d5441929d44dabeefb1b6238bb93b
Autor:
Kerry S. Campbell, Adam D. Cohen, Michael D. Robbins, Natalie A. Bezman, Robert F. Graziano, Alper Y. Kearney, Amy Jhatakia, Andrew Gale, Yibin Yang, Kimberly B. Colby, Ashley M. James, Tatiana Pazina
Elotuzumab (Elo) is an IgG1 monoclonal antibody targeting SLAMF7 (CS1, CRACC, and CD319), which is highly expressed on multiple myeloma (MM) cells, natural killer (NK) cells, and subsets of other leukocytes. By engaging with FcγRIIIA (CD16), Elo pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4dfd4fed3099da2d18527a6c9fd1f00e
https://doi.org/10.1158/2326-6066.c.6549927.v1
https://doi.org/10.1158/2326-6066.c.6549927.v1
Autor:
Kerry S. Campbell, Adam D. Cohen, Michael D. Robbins, Natalie A. Bezman, Robert F. Graziano, Alper Y. Kearney, Amy Jhatakia, Andrew Gale, Yibin Yang, Kimberly B. Colby, Ashley M. James, Tatiana Pazina
Supplementary Figures 1-9
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92c1c3d238ebeff235065d4da790ca40
https://doi.org/10.1158/2326-6066.22542438.v1
https://doi.org/10.1158/2326-6066.22542438.v1
Autor:
Irene M. Ghobrial, Jamil Azzi, Michael D. Robbins, Yu-Tzu Tai, Daisy Huynh, Antonio Sacco, Chia-Jen Liu, Alexandre Detappe, Aldo Roccaro, Yuji Mishima, Michele Moschetta, Salomon Manier, Jennifer L. Guerriero, Amy Jhatakia, Natalie A. Bezman, Siobhan V. Glavey, Ahmed T. Kurdi
Supplementary Figure 1. In-vivo mouse model's schema; Supplementary Figure 2. Total BLI Flux of SCID.beige myeloma xenograft model and Kaplan-Meier survival analysis of the NSG xenograft model; Supplementary Figure 3. Elotuzumab does not affect myelo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66b816a97b9fef9eac8cec3db8a996da
https://doi.org/10.1158/1535-7163.22505803
https://doi.org/10.1158/1535-7163.22505803
Autor:
Irene M. Ghobrial, Jamil Azzi, Michael D. Robbins, Yu-Tzu Tai, Daisy Huynh, Antonio Sacco, Chia-Jen Liu, Alexandre Detappe, Aldo Roccaro, Yuji Mishima, Michele Moschetta, Salomon Manier, Jennifer L. Guerriero, Amy Jhatakia, Natalie A. Bezman, Siobhan V. Glavey, Ahmed T. Kurdi
Elotuzumab, a recently approved antibody for the treatment of multiple myeloma, has been shown to stimulate Fcγ receptor (FcγR)-mediated antibody-dependent cellular cytotoxicity by natural killer (NK) cells toward myeloma cells. The modulatory effe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d170a9010f2820977fff9f1159ce1812
https://doi.org/10.1158/1535-7163.c.6538189.v1
https://doi.org/10.1158/1535-7163.c.6538189.v1
Autor:
Claire Friedman, Richard Carvajal, Diwakar Davar, Eduardo Castanon, Paolo Ascierto, Emiliano Calvo, Mark O'Hara, Steven Powell, Ronnie Shapira-Frommer, Elena Garralda, Daniel John Renouf, Ruth Perets, Mona Yunan, Palanikumar Ravindran, Amy Hammell, Shaun O’Brien, Ke Xu, Nicholas Wilson, Amy Jhatakia, Anandaroop Mukhopadhyay, Martin Gutierrez
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::166c628781ac35a6e708c43ad76057ad
https://doi.org/10.1136/jitc-2022-sitc2022.0592
https://doi.org/10.1136/jitc-2022-sitc2022.0592
Autor:
Christine Bee, Olafur S. Gudmundsson, Guodong Chen, Amy Jhatakia, Andy X. Deng, Natalie Bezman, Richard Y.-C. Huang, Yun Wang, Vangipuram S. Rangan, Shrikant Deshpande
Publikováno v:
Journal of the American Society for Mass Spectrometry. 32:1567-1574
NK group 2 member A (NKG2A), an immune checkpoint inhibitor, is an emerging therapeutic target in immuno-oncology. NKG2A forms a heterodimer with CD94 on the cell surface of NK and a subset of T cells and recognizes the nonclassical human leukocyte a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::244d9a1f0bc932e2c7ea1e99d2b03c5e
https://doi.org/10.1021/jasms.0c00399
https://doi.org/10.1021/jasms.0c00399
Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab
Autor:
Irene M. Ghobrial, Natalie Bezman, Michele Moschetta, Antonio Sacco, Aldo M. Roccaro, Yu-Tzu Tai, Daisy Huynh, Siobhan Glavey, Yuji Mishima, Alexandre Detappe, Jamil Azzi, Jennifer L. Guerriero, Ahmed T. Kurdi, Amy Jhatakia, Chia Jen Liu, Michael Robbins, Salomon Manier
Publikováno v:
Molecular Cancer Therapeutics. 17:1454-1463
Elotuzumab, a recently approved antibody for the treatment of multiple myeloma, has been shown to stimulate Fcγ receptor (FcγR)-mediated antibody-dependent cellular cytotoxicity by natural killer (NK) cells toward myeloma cells. The modulatory effe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec92fb0b19db5452c6933c7740a3f8c7
https://doi.org/10.1158/1535-7163.mct-17-0998
https://doi.org/10.1158/1535-7163.mct-17-0998
Viral Infections and Autoimmune Disease: Roles of LCMV in Delineating Mechanisms of Immune Tolerance
Autor:
Georgia Fousteri, Amy Jhatakia
Viral infections are a natural part of our existence. They can affect us in many ways that are the result of the interaction between the viral pathogen and our immune system. Most times the resulting immune response is beneficial for the host. The pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d146a2607fcbb41f51566716995f3dae
https://doi.org/10.20944/preprints201907.0134.v2
https://doi.org/10.20944/preprints201907.0134.v2
Autor:
Amy Jhatakia, Kristine A. Frerichs, Marloes E. C. Broekmans, Natalie Bezman, Tuna Mutis, Christie P. M. Verkleij, Niels W.C.J. van de Donk, Sonja Zweegman
Publikováno v:
Cancers, 12(12):3713, 1-20. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers
Cancers, Vol 12, Iss 3713, p 3713 (2020)
Verkleij, C P M, Jhatakia, A, Broekmans, M E C, Frerichs, K A, Zweegman, S, Mutis, T, Bezman, N A & van de Donk, N W C J 2020, ' Preclinical rationale for targeting the PD-1/PD-L1 axis in combination with a CD38 antibody in multiple myeloma and other CD38- positive malignancies ', Cancers, vol. 12, no. 12, 3713, pp. 1-20 . https://doi.org/10.3390/cancers12123713
Volume 12
Issue 12
Cancers
Cancers, Vol 12, Iss 3713, p 3713 (2020)
Verkleij, C P M, Jhatakia, A, Broekmans, M E C, Frerichs, K A, Zweegman, S, Mutis, T, Bezman, N A & van de Donk, N W C J 2020, ' Preclinical rationale for targeting the PD-1/PD-L1 axis in combination with a CD38 antibody in multiple myeloma and other CD38- positive malignancies ', Cancers, vol. 12, no. 12, 3713, pp. 1-20 . https://doi.org/10.3390/cancers12123713
Volume 12
Issue 12
The CD38-targeting antibody daratumumab mediates its anti-myeloma activities not only through Fc-receptor-dependent effector mechanisms, but also by its effects on T-cell immunity through depletion of CD38+ regulatory T-cells, regulatory B-cells, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::378a42f70bea47e0a34986279eda8df1
https://doi.org/10.3390/cancers12123713
https://doi.org/10.3390/cancers12123713